{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:59:14Z","timestamp":1790427554234,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1124\/mol.115.101980","type":"journal-article","created":{"date-parts":[[2015,12,23]],"date-time":"2015-12-23T23:05:36Z","timestamp":1450911936000},"page":"364-375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease"],"prefix":"10.1016","volume":"89","author":[{"given":"Robert B.","family":"Laprairie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina M.","family":"Bagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie E.M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"Denovan-Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/mol.115.101980_bib1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejphar.2013.09.002","article-title":"Co-expression of the human cannabinoid receptor coding region splice variants (hCB\u2081) affects the function of hCB\u2081 receptor complexes","volume":"721","author":"Bagher","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/mol.115.101980_bib2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.neuroscience.2007.03.010","article-title":"Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington\u2019s disease","volume":"147","author":"Benn","year":"2007","journal-title":"Neuroscience"},{"key":"10.1124\/mol.115.101980_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1098\/rspb.1983.0093","article-title":"Operational models of pharmacological agonism","volume":"220","author":"Black","year":"1983","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"10.1124\/mol.115.101980_bib4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.neuropharm.2009.06.007","article-title":"Prolonged exposure to WIN55,212\u20132 causes downregulation of the CB1 receptor and the development of tolerance to its anticonvulsant effects in the hippocampal neuronal culture model of acquired epilepsy","volume":"57","author":"Blair","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1124\/mol.115.101980_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/brain\/awq278","article-title":"Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington\u2019s disease","volume":"134","author":"Bl\u00e1zquez","year":"2011","journal-title":"Brain"},{"key":"10.1124\/mol.115.101980_bib6","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/cdd.2015.11","article-title":"The CB\u2081 cannabinoid receptor signals striatal neuroprotection via a PI3K\/Akt\/mTORC1\/BDNF pathway","volume":"22","author":"Bl\u00e1zquez","year":"2015","journal-title":"Cell Death Differ"},{"key":"10.1124\/mol.115.101980_bib7","doi-asserted-by":"crossref","unstructured":"Botelho EP, Wang E, Chen JY, Holley S, Andre V, Cepeda C, and Levine MS (2014) Differential synaptic and extrasynaptic glutamate-receptor alterations in striatal medium-sized spiny neurons of aged yac128 Huntington\u2019s disease Mice. PLoS Curr 6 DOI: 10.1371\/currents.hd.34957c4f8bd7cb1f5ec47381dfc811c3.","DOI":"10.1371\/currents.hd.34957c4f8bd7cb1f5ec47381dfc811c3"},{"key":"10.1124\/mol.115.101980_bib8","doi-asserted-by":"crossref","first-page":"8257","DOI":"10.1073\/pnas.1400988111","article-title":"A restricted population of CB1 cannabinoid receptors with neuroprotective activity","volume":"111","author":"Chiarlone","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.115.101980_bib9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1124\/mol.114.094342","article-title":"Advances in G protein-coupled receptor allostery: from function to structure","volume":"86","author":"Christopoulos","year":"2014","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.115.101980_bib10","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","article-title":"Controlled clinical trial of cannabidiol in Huntington\u2019s disease","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/mol.115.101980_bib11","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1556-4029.2012.02068.x","article-title":"Evolution of the content of THC and other major cannabinoids in drug-type cannabis cuttings and seedlings during growth of plants","volume":"57","author":"De Backer","year":"2012","journal-title":"J Forensic Sci"},{"key":"10.1124\/mol.115.101980_bib12","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"key":"10.1124\/mol.115.101980_bib13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0306-4522(00)00157-3","article-title":"Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington\u2019s disease mice","volume":"98","author":"Denovan-Wright","year":"2000","journal-title":"Neuroscience"},{"key":"10.1124\/mol.115.101980_bib14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.neuroscience.2010.06.056","article-title":"Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington\u2019s disease transgenic mice","volume":"170","author":"Dowie","year":"2010","journal-title":"Neuroscience"},{"key":"10.1124\/mol.115.101980_bib16","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.tips.2015.05.008","article-title":"Functional studies cast light on receptor states","volume":"36","author":"Ehlert","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/mol.115.101980_bib17","first-page":"e3179","article-title":"Quantifying agonist activity at G protein-coupled receptors","volume":"58","author":"Ehlert","year":"2011","journal-title":"J Vis Exp"},{"key":"10.1124\/mol.115.101980_bib18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1476-5381.2008.00088.x","article-title":"The endocannabinoid system as a target for the treatment of motor dysfunction","volume":"156","author":"Fern\u00e1ndez-Ruiz","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1124\/mol.115.101980_bib19","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1523\/JNEUROSCI.17-14-05327.1997","article-title":"Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor","volume":"17","author":"Glass","year":"1997","journal-title":"J Neurosci"},{"key":"10.1124\/mol.115.101980_bib20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","article-title":"The pattern of neurodegeneration in Huntington\u2019s disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington\u2019s disease","volume":"97","author":"Glass","year":"2000","journal-title":"Neuroscience"},{"key":"10.1124\/mol.115.101980_bib21","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1124\/jpet.107.120857","article-title":"Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi\/o,Gs, and G15","volume":"321","author":"Griffin","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/mol.115.101980_bib22","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.neuropharm.2008.06.040","article-title":"Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism","volume":"55","author":"Hayakawa","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1124\/mol.115.101980_bib23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/ejn.12045","article-title":"Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington\u2019s disease and mouse models","volume":"37","author":"Horne","year":"2013","journal-title":"Eur J Neurosci"},{"key":"10.1124\/mol.115.101980_bib24","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nmeth978","article-title":"A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer","volume":"3","author":"James","year":"2006","journal-title":"Nat Methods"},{"key":"10.1124\/mol.115.101980_bib25","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00210-006-0033-x","article-title":"Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors","volume":"372","author":"Kathmann","year":"2006","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/mol.115.101980_bib26","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1124\/mol.104.006882","article-title":"Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?","volume":"67","author":"Kearn","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.115.101980_bib27","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrd3954-c2","article-title":"Measurements of ligand bias and functional affinity","volume":"12","author":"Kenakin","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/mol.115.101980_bib28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1021\/cn200111m","article-title":"A simple method for quantifying functional selectivity and agonist bias","volume":"3","author":"Kenakin","year":"2012","journal-title":"ACS Chem Neurosci"},{"key":"10.1124\/mol.115.101980_bib29","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1124\/mol.115.099192","article-title":"Biased agonism and biased allosteric modulation at the CB1 cannabinoid receptor","volume":"88","author":"Khajehali","year":"2015","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.115.101980_bib30","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejmg.2013.05.007","article-title":"CNR1 variation is associated with the age at onset in Huntington disease","volume":"56","author":"Kloster","year":"2013","journal-title":"Eur J Med Genet"},{"key":"10.1124\/mol.115.101980_bib31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0014-5793(98)00581-X","article-title":"2-Arachidonoylglycerol, an endogenous cannabinoid receptor agonist: identification as one of the major species of monoacylglycerols in various rat tissues, and evidence for its generation through CA2+-dependent and -independent mechanisms","volume":"429","author":"Kondo","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1124\/mol.115.101980_bib32","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1212\/WNL.0000000000000363","article-title":"Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"82","author":"Koppel","year":"2014","journal-title":"Neurology"},{"key":"10.1124\/mol.115.101980_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.gene.2014.11.022","article-title":"Huntington\u2019s disease: an update of therapeutic strategies","volume":"556","author":"Kumar","year":"2015","journal-title":"Gene"},{"key":"10.1124\/mol.115.101980_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.neuropharm.2013.04.006","article-title":"Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: implications for Huntington\u2019s disease","volume":"72","author":"Laprairie","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1124\/mol.115.101980_bib35","doi-asserted-by":"crossref","first-page":"24845","DOI":"10.1074\/jbc.M114.557025","article-title":"Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons","volume":"289","author":"Laprairie","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.115.101980_bib36","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1124\/mol.115.101980_bib37","doi-asserted-by":"crossref","first-page":"19144","DOI":"10.1073\/pnas.0509588102","article-title":"The cannabinoid agonist WIN55,212\u20132 increases intracellular calcium via CB1 receptor coupling to Gq\/11 G proteins","volume":"102","author":"Lauckner","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.115.101980_bib38","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1124\/mol.115.099630","article-title":"Fulfilling the promise of \u201cbiased\u201d G protein-coupled receptor agonism","volume":"88","author":"Luttrell","year":"2015","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.115.101980_bib39","first-page":"303","article-title":"Quantitative fluorescence measurements of cell viability (cytotoxicity) with a multi-well plate scanner","volume":"111","author":"MacCoubrey","year":"1990","journal-title":"J Cell Biol"},{"key":"10.1124\/mol.115.101980_bib40","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1111\/j.1432-1033.2004.04460.x","article-title":"Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington\u2019s disease transgenic mice","volume":"271","author":"McCaw","year":"2004","journal-title":"Eur J Biochem"},{"key":"10.1124\/mol.115.101980_bib41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1042\/bj2750175","article-title":"Cholera toxin impairment of opioid-mediated inhibition of adenylate cyclase in neuroblastoma x glioma hybrid cells is due to a toxin-induced decrease in opioid receptor levels","volume":"275","author":"McKenzie","year":"1991","journal-title":"Biochem J"},{"key":"10.1124\/mol.115.101980_bib42","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bph.12944","article-title":"Are cannabidiol and \u0394(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review","volume":"172","author":"McPartland","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1124\/mol.115.101980_bib43","first-page":"178","article-title":"Medical marijuana in Huntington\u2019s disease: report of two cases","volume":"95","author":"Meisel","year":"2012","journal-title":"Med Health R I"},{"key":"10.1124\/mol.115.101980_bib44","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.nbd.2011.03.006","article-title":"Worsening of Huntington disease phenotype in CB1 receptor knockout mice","volume":"42","author":"Mievis","year":"2011","journal-title":"Neurobiol Dis"},{"key":"10.1124\/mol.115.101980_bib45","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1042\/bj2620643","article-title":"Cholera toxin treatment produces down-regulation of the alpha-subunit of the stimulatory guanine-nucleotide-binding protein (Gs)","volume":"262","author":"Milligan","year":"1989","journal-title":"Biochem J"},{"issue":"Suppl 3","key":"10.1124\/mol.115.101980_bib46","first-page":"23","article-title":"Cannabis in movement disorders","volume":"6","author":"M\u00fcller-Vahl","year":"1999","journal-title":"Forsch Komplementarmed"},{"key":"10.1124\/mol.115.101980_bib47","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.nbd.2014.08.009","article-title":"Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice","volume":"71","author":"Naydenov","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.1124\/mol.115.101980_bib48","doi-asserted-by":"crossref","first-page":"21134","DOI":"10.1073\/pnas.1202906109","article-title":"Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor","volume":"109","author":"Pamplona","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.115.101980_bib49","doi-asserted-by":"crossref","first-page":"10090","DOI":"10.1523\/JNEUROSCI.3237-08.2008","article-title":"Dopaminergic and glutamatergic signaling crosstalk in Huntington\u2019s disease neurodegeneration: the role of p25\/cyclin-dependent kinase 5","volume":"28","author":"Paoletti","year":"2008","journal-title":"J Neurosci"},{"key":"10.1124\/mol.115.101980_bib50","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neuropharm.2013.03.027","article-title":"Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors","volume":"71","author":"Pazos","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1124\/mol.115.101980_bib51","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1369-1600.2008.00108.x","article-title":"Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond","volume":"13","author":"Pertwee","year":"2008","journal-title":"Addict Biol"},{"key":"10.1124\/mol.115.101980_bib52","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem Res"},{"key":"10.1124\/mol.115.101980_bib53","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1124\/mol.115.101980_bib54","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1111\/j.1460-9568.2006.04871.x","article-title":"Huntingtin inclusions do not down-regulate specific genes in the R6\/2 Huntington\u2019s disease mouse","volume":"23","author":"Sadri-Vakili","year":"2006","journal-title":"Eur J Neurosci"},{"key":"10.1124\/mol.115.101980_bib55","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/jnr.22682","article-title":"Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington\u2019s disease","volume":"89","author":"Sagredo","year":"2011","journal-title":"J Neurosci Res"},{"key":"10.1124\/mol.115.101980_bib56","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1460-9568.2007.05717.x","article-title":"Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors","volume":"26","author":"Sagredo","year":"2007","journal-title":"Eur J Neurosci"},{"key":"10.1124\/mol.115.101980_bib57","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1124\/jpet.102.035618","article-title":"Effect of chronic administration of R-(+)-[2,3-Dihydro\u20135-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212\u20132) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice","volume":"303","author":"Sim-Selley","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/mol.115.101980_bib58","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/hmg\/9.19.2799","article-title":"Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells","volume":"9","author":"Trettel","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1124\/mol.115.101980_bib59","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1021\/cn200114w","article-title":"Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington\u2019s disease: role of CB1 and CB2 receptors","volume":"3","author":"Valdeolivas","year":"2012","journal-title":"ACS Chem Neurosci"},{"key":"10.1124\/mol.115.101980_bib60","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2967\/jnumed.110.077156","article-title":"Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo","volume":"51","author":"Van Laere","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1124\/mol.115.101980_bib61","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrd4052","article-title":"Emerging paradigms in GPCR allostery: implications for drug discovery","volume":"12","author":"Wootten","year":"2013","journal-title":"Nat Rev Drug Discov"}],"updated-by":[{"DOI":"10.1124\/mol.115.101980err","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000}}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24004565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24004565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.115.101980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:34:58Z","timestamp":1743381298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24004565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0026895X24004565"],"URL":"https:\/\/doi.org\/10.1124\/mol.115.101980","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.115.101980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}